Federal grant · project grant (b)
Direct Proteolytic Machine Assessments for Unfolding and Sequencing Proteins - Project Summary Protein Sequencing Is a Cornerstone of Proteomics, Offering Crucial Insights Into the Molecular Underpinnings of Biological Processes and Diseases. However, Current Proteomic Tools, Such as Mass Spectrometry (MS), Immunoassays, and Protein Cataloging Approaches, Are Limited by High Costs, Low Throughput, and an Inability to Perform Comprehensive De Novo Protein Sequencing. These Limitations Hinder the Accurate Characterization of Low-abundance Proteins and the Sequencing and Quantification of Post-translational Modifications (PTMS), Single Nucleotide Polymorphisms (SNPS), and Splicing Variants, Making Proteome-wide Analysis Challenging. Given These Constraints and the Growing Demand for More Comprehensive Proteomic Analysis, There Is a Significant Opportunity to Develop More Efficient, Cost-effective, and Scalable Protein Sequencing Methods. in Response, Electronic Biosciences, Inc. (EBS) Proposes to Develop and Demonstrate a Novel Enzyme-based, Single- Molecule Protein Sequencing System. This Innovative Platform Will Leverage Enzyme-driven Processing and Sequencing of Individual Proteins and Peptides, Combined With Advanced Bioinformatics, to Achieve High Accuracy and Throughput. During This Phase I Program, We Will Develop and Optimize This Single-molecule Sequencing Approach, Demonstrating Its Ability to Accurately Sequence Peptides With Various PTMS, Surpassing the Capabilities of Current State-of-the-art Methods. by Integrating Enzymatic Assessments With Sophisticated Sequencing Algorithms, Our System Aims to Enable Scalable, Multiplexed Protein Sequencing, Capable of Analyzing All Proteins and Peptides in a Given Sample. Our Proposed System Will Not Only Be Rapid, Reliable, and Low-cost But Also Accessible for a Wide Range of Applications, From Basic Research to Clinical Diagnostics. This Technology Has the Potential to Revolutionize Protein Analysis, Facilitating Rapid Biomarker Discovery and Enhancing Disease Testing and Monitoring, Ultimately Advancing Biomedical Research and Public Health.
Committed
$350,000
Paid out
$113.5K
32%
Committed, not yet paid
$236.5K
68%
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.